[Adalimumab for therapy of rheumatoid arthritis].
Eguchi
Katsumi
K
First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University.
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D001175:Arthrography; D003141:Communicable Diseases / Q000209:etiology; D003711:Demyelinating Diseases / Q000209:etiology; D018450:Disease Progression; D006801:Humans; D007596:Joints / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000209:etiology; D009369:Neoplasms / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000378:metabolism; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000378:metabolism; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab